Petrovax Pharm

Petrovax Pharm company information, Employees & Contact Information

Explore related pages

Related company profiles:

Petrovax is a company of novel biopharmaceutical practices with 28 years of successful experience. The product portfolio includes original pharmaceutical products and vaccines, biotechnology drugs, branded generics and food supplements. Petrovax is the holder of patents for molecules and pharmaceutical manufacturing technologies in Russia and abroad. Its own R&D center for pre-clinical studies enables a full cycle of drug development. Petrovax’s modern manufacturing complex in the Moscow Region operates in full compliance with the EAEU and EU GMP standards. The synthesis of APIs, sterile and non-sterile pharmaceutical forms production is performed at the manufacturing complex. The annual production capacity is 160 million doses. The company is one of the largest Russian exporters of original medicinal products and vaccines, which are supplied to EAEU and EU countries. Petrovax is a partner of international Big Pharma companies: Pfizer, Abbott, ISU ABXIS, Adimmune, Hengrui. The development strategy focuses on providing patients with in-demand vaccines and medicines for the prevention and treatment of socially significant conditions, such as infectious, oncological, and orphan diseases. Petrovax has over 700 employees. The company's vision: "Leading pharmaceutical innovations". Our mission: "Expanding access to cutting-edge therapies".

Company Details

Employees
93
Founded
-
Address
1 Sosnovaya St., Pokrov Village, Podolsk, Moscow Region,142143 Russia, Moscow,russia 142143,russian Federation
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Moscow, Russia
Looking for a particular Petrovax Pharm employee's phone or email?

Petrovax Pharm Questions

News

Petrovax Pharm and Gamaleya Center have agreed to produce a drug for nasopharyngeal and esophageal cancer - Новости GxP

Petrovax Pharm and Gamaleya Center have agreed to produce a drug for nasopharyngeal and esophageal cancer Новости GxP

Petrovax begins dosing in Phase III trial of CanSino’s Covid-19 vaccine - Clinical Trials Arena

Petrovax begins dosing in Phase III trial of CanSino’s Covid-19 vaccine Clinical Trials Arena

Petrovax announces positive results from long-CoV-III-21 trial of Longidaza for long-term pulmonary sequelae of COVID-19 - Pharmaceutical Technology

Petrovax announces positive results from long-CoV-III-21 trial of Longidaza for long-term pulmonary sequelae of COVID-19 Pharmaceutical Technology

Boehringer Ingelheim and Cipla transferring manufacturing tech to Russian companies - Fierce Pharma

Boehringer Ingelheim and Cipla transferring manufacturing tech to Russian companies Fierce Pharma

Russian Vaccine Team in Talks With China on Combination Trial - Bloomberg

Russian Vaccine Team in Talks With China on Combination Trial Bloomberg

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae - News-Medical

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae News-Medical

Pfizer Touts Local Partnership - The Moscow Times

Pfizer Touts Local Partnership The Moscow Times

Russia blocks Abbott Laboratories - Petrovax merger - domain-b.com

Russia blocks Abbott Laboratories - Petrovax merger domain-b.com

The Ministry of Health has registered the first Russian biosimilar of denosumab for the treatment of osteoporosis - Новости GxP

The Ministry of Health has registered the first Russian biosimilar of denosumab for the treatment of osteoporosis Новости GxP

Petrovax is ready to participate in auctions after the price of Prevenar 13 vaccine is reviewed - Новости GxP

Petrovax is ready to participate in auctions after the price of Prevenar 13 vaccine is reviewed Новости GxP

Petrovax will introduce Chinese camrelizumab to the Russian market - Новости GxP

Petrovax will introduce Chinese camrelizumab to the Russian market Новости GxP

Top Petrovax Pharm Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant